PT  - JOURNAL ARTICLE
AU  - Gwen van der Wijk
AU  - Yaruuna Enkhbold
AU  - Kelsey Cnudde
AU  - Matt W. Szostakiwskyj
AU  - Pierre Blier
AU  - Verner Knott
AU  - Natalia Jaworska
AU  - Andrea B. Protzner
TI  - One size does not fit all: Single-subject analyses reveal substantial individual variation in electroencephalography (EEG) characteristics of antidepressant treatment response
AID  - 10.1101/2020.11.09.20227280
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.09.20227280
4099  - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20227280.short
4100  - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20227280.full
AB  - Background Electroencephalography (EEG) characteristics associated with treatment response show potential for informing treatment choices for major depressive disorder, but to date, no robust markers have been identified. Variable findings might be due to the use of group analyses on a relatively heterogeneous population, which neglect individual variation. However, the correspondence between group level findings and individual brain characteristics has not been extensively investigated. Using single-subject analyses, we explored the extent to which group-based EEG connectivity and complexity characteristics associated with treatment response could be identified in individual patients.Methods Resting-state EEG data and Montgomery-Åsberg Depression Rating Scale symptom scores were collected from 43 patients with depression (23 females) before, at 1 and 12 weeks of treatment with escitalopram, bupropion or both. The multivariate statistical technique partial least squares was used to: 1) identify differences in EEG connectivity (weighted phase lag index) and complexity (multiscale entropy) between responders and non-responders to treatment (≥50% and <50% reduction in symptoms, respectively, by week 12), and 2) determine whether group patterns could be identified in individual patients.Results The group analyses distinguished groups. Responders showed decreased alpha and increased beta connectivity and early, widespread decreases in coarse scale entropy over treatment. Non-responders showed an opposite connectivity pattern, and later, spatially confined decreases in coarse scale entropy. These EEG characteristics were identified in ∼40-60% of individual patients.Conclusion Substantial individual variation highlighted by the single-subject analyses might explain why robust EEG markers of antidepressant treatment response have not been identified. As up to 60% of patients in our sample was not well represented by the group results, individual variation needs to be considered when investigating clinically useful characteristics of antidepressant treatment response.Competing Interest StatementP.B. received honoraria for lectures and/or participation in advisory boards for Allergan, Janssen, Lundbeck, Otsuka, Pfizer, Pierre Fabre Medicaments, Sunovion and Takeda. He has provided expert testimony on behalf of Bristol Myers Squibb and Otsuka. These industries had no influence on the work presented herein. G.W., Y.E., K.C., M.W.S, V.K., N.J. and A.B.P have no conflicts of interest to declare.Clinical TrialNCT00519428Funding StatementPatients in this study were recruited from an NIH-funded clinical trial (5R01MH077285). We acknowledge support to G.W. in the form of a Mamdani Family Foundation Graduate Scholarship and Alberta Graduate Excellence Scholarship (AGES: International), and N.J. and A.B.P. from the Natural Sciences and Engineering Council of Canada (NSERC; RGPIN-2018-06869 and RGPIN-2020-05299 respectively).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Royal Ottawa Health Care Group and University of Ottawa Social Sciences & Humanities Research Ethics Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed here were collected as part of a larger randomized clinical trial. Information about the clinical trial can be found here: https://clinicaltrials.gov/ct2/show/NCT00519428